共病纤维肌痛对中轴型脊柱关节炎疾病活动度评估及肿瘤坏死因子抑制剂疗效的影响:英国国家登记研究结果
该研究在英国83个中心前瞻性纳入1757例中轴型脊柱关节炎患者,22.1%符合2011年纤维肌痛标准。共病纤维肌痛者疾病活动度更高(BASDAI平均差1.04,95%CI 0.75-1.33)、生活质量更差(ASQoL差1.42,95%CI 0.88-1.96),但对12个月TNFi治疗达标率无显著影响。
要点
- 22.1%的中轴型脊柱关节炎患者符合纤维肌痛标准,其BASDAI平均高1.04、ASQoL差1.42。
- 291例起始生物制剂者中,共病纤维肌痛者基线BASDAI高2.0,12个月时高1.1。
- 12个月ASAS20达标率无显著差异,纤维肌痛症状严重度量表高分者TNFi改善更少。
核心结论
- 符合纤维肌痛标准对中轴型脊柱关节炎疾病活动度和生活质量的评估有适度影响,但不显著影响生物制剂治疗反应。
- 纤维肌痛评估中症状严重度量表高分的患者可能从针对纤维肌痛的额外专项管理中获益。
研究设计与样本
- 前瞻性研究,在英国83个中心招募中轴型脊柱关节炎患者。
- 共1757例参与者符合分析条件,采用2011年纤维肌痛标准,用多变量线性回归模型评估符合纤维肌痛标准对疾病活动度、生活质量和TNFi治疗反应的影响。
主要发现
- 1757例中22.1%符合纤维肌痛标准。
- 调整人口学、临床和生活方式因素后,符合纤维肌痛标准者疾病活动度更高,BASDAI平均差(纤维肌痛阳性减阴性)为1.04(95%CI 0.75,1.33)。
- 符合纤维肌痛标准者生活质量更差,ASQoL评分差为1.42(95%CI 0.88,1.96)。
- 291例起始生物制剂治疗者中,共病纤维肌痛者基线BASDAI评分高2.0,12个月时高1.1。
- 12个月时达到ASAS20标准的可能性无显著差异;3个月TNFi治疗中疾病活动度和生活质量改善较少与纤维肌痛标准症状严重度量表高分关系最强。
关键数值与推荐
- 纤维肌痛标准采用2011年标准。
- BASDAI平均差(纤维肌痛阳性减阴性)1.04(95%CI 0.75,1.33)。
- ASQoL评分差1.42(95%CI 0.88,1.96)。
- 291例起始生物制剂者中,共病纤维肌痛者基线BASDAI高2.0,12个月时高1.1。
- 12个月ASAS20达标率无显著差异。
临床怎么用
- 原文结论指出,纤维肌痛评估中症状严重度量表高分的患者可能从针对纤维肌痛的额外专项管理中获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To quantify the extent to which co-morbid FM is associated with higher disease activity, worse quality of life (QoL) and poorer response to TNF inhibitors (TNFis) in patients with axial SpA. METHODS: A prospective study recruiting across 83 centres in the UK. Clinical information and patient-reported measures were available, including 2011 criteria for FM. Multivariable linear regression was used to model the effect of meeting the FM criteria on disease activity, QoL and response to TNFis. RESULTS: A total of 1757 participants were eligible for analyses, of whom 22.1% met criteria for FM. Those with co-morbid FM criteria had higher disease activity [BASDAI average difference FM+ - FM- 1.04 (95% CI 0.75, 1.33)] and worse QoL [Ankylosing Spondylitis Quality of Life score difference 1.42 (95% CI 0.88, 1.96)] after adjusting for demographic, clinical and lifestyle factors. Among 291 participants who commenced biologic therapy, BASDAI scores in those with co-morbid FM were 2.0 higher at baseline but decreased to 1.1 higher at 12 months. There was no significant difference in the likelihood of meeting Assessment of SpondyloArthritis international Society 20 criteria at 12 months. Less improvement in disease activity and QoL over 3 months of TNFi therapy was most strongly related to high scores on the FM criteria symptom severity scale component. CONCLUSION: Fulfilling criteria for FM has a modest impact on the assessment of axial SpA disease activity and QoL and does not significantly influence response to biologic therapy. Those with a high symptom severity scale on FM assessment may benefit from additional specific management for FM.
引用
- Macfarlane GJ, MacDonald RIR, Pathan E, et al. Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. Rheumatology (Oxford). 2018. PMID: 30053166. doi:10.1093/rheumatology/key206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。